Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProDERM: Octagam 10% in Dermatomyositis
NCT02728752Phase 3Completed
- Sponsor
- Octapharma
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of human normal immunoglobulin in dermatomyositis (DM), sponsored by Octapharma. Started Feb 2017; status: completed.
02
Drugs
human normal immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02728752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728752.